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ackground: Sickle cell disease (SCD) is an autosomal recessive disease caused by a single gene 
mutation, leading to sickle-shaped red blood cells, causing many clinical complications. Resulting 
complications may affect the growth of the SCD patients that is a strong measure of severity of disease 
and helps in disease management strategies in any area.  Eastern province of Saudi Arabia has one of the 
highest SCD incidences. Nevertheless, no studies have been previously carried out of about clinical outcome of 
SCD in Al-Ahsa area of eastern province. Therefore, this study was conducted to find out the impact of SCD 
children at king Abdulaziz Hospital Al-Ahsa.  
Methods: All pediatric SCD patients were included in the study. Patient data was taken from hospital information 
system and analyzed using SPSS version 27.  
Results: A total of 53 patients were studied. The male to female ratio was 1.4:1 and mean age was 3.3 years 
(range: 1-9). Eighteen (34%) did not present with sickle cell crisis possibly due to ameliorating effects of high 
HbF and G6PD deficiency. Although growth parameters of SCD patients were not statistically different from 
international standards, there was significant difference between weight of SCD patients in recurrent sickle cell 
crisis group and non-crisis sickle cell (NC-SC) group at diagnosis and after clinical interventions (p= 0.04 and 
0.03, respectively) that included hydroxyurea. The corrected reticulocyte (at diagnosis and after clinical 
intervention) and WBC counts were statistically significant between hydroxyurea and non-hydroxyurea groups 
(p-value < 0.05).  
Conclusions: Overall, one-third of SCD patients in Al-Ahsa region have mild disease and hydroxyurea can 
minimize the SCD severity through lowering corrected reticulocyte and WBC counts. Exact mechanisms of mild 
SCD and hydroxyurea in minimizing disease severity are needed to be elucidated.    
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Introduction  
Sickle cell anemia is an inherited disease with the 
production of sickled red blood cells and hemoglobin S 
instead of hemoglobin A [1]. Consequently, 
hemoglobin’s ability of transferring oxygen all over the 
body decreases. Moreover, normal red blood cells’ life 
span is 120 days, but in sickle cell anemia, red blood 
cells last for 10-20 days [2,3] The diagnosis of sickle cell 
anemia is performed by a hemoglobin electrophoresis to 
check for hemoglobin S and this blood test is part of the 
routine newborn screening in Saudi Arabia.  
Sickle cell anemia patients experience many 
symptoms that vary from person to person which include 
fatigue, episodes of pain, painful swelling of limbs, 
frequent infections, delayed growth, and vision problems 
[4]. Sickle cell anemia affects a lot of body functions and 
causes some serious complications. The most common 
complications among sickle cell anemia patients are the 
retention of blood in limbs due to blood vessels 
obstruction, and this is known as hand-foot syndrome [5]. 
The sickled cells stick to wall of blood vessels and block 
the blood flow to the different body organs. When blood 
vessels are blocked, oxygen and nutrients will not be 
able to reach organs, and that will lead to organ 
dysfunction and death. A cure for sickle cell anemia is 
unavailable, so medication is usually taken to help with 
complications. For instance, hydroxyurea is 
administered to prevent pain [6]. In case the patient is 
having a pain episode, medication is given based on the 
severity of the crisis like aspirin for mild to moderate pain 
and opioid (morphine) for severe pain. Blood 
transfusions are effective to compensate the function of 
the sickled cells [6].  
Sickle cell disease can severely affect growth of the 
children, in addition to other clinical manifestations [2, 4]. 
There are different reports about impact of sickle cell 
disease on children growth. A study carried in India in 
2004 reported that children with sickle cell anemia had 
lower weight and height [7, 8]. In another study 
conducted in US on children and adolescents aged 6 to 
18 years, no significant changes in height or weight of 
SCD children were noted as compared to healthy 
population [9]. A study conducted in Philadelphia 
showed that children with sickle cell anemia had low 
bone mineral density maturation [10]. Studies have 
shown that sickle cell disease can have varying effects 
on growth and other health parameters in different ethnic 
groups that may be due to different SCD phenotypes in 
different geographic regions of the world [11].  Moreover, 
various clinical complications resulting due to SCD may 
affect the growth of the SCD patients that is a strong 
measure of severity of disease and helps in disease 
management strategies in any area.   
The incidence of SCD and its phenotypes vary in 
different parts of Saudi Arabia [8, 12]. The prevalence of 
SCD trait varies from 2-27% in different parts of Saudi 
Arabia while disease has a severe and a mild phenotype 
[8, 12]. Although many studies have been conducted in 
Saudi Arabia about sickle cell disease, no study has 
been carried out in Al-Ahsa region about impact of sickle 
cell anemia on growth parameters (height, weight) of 
sickle cell patients. Therefore, objective of this study is to 
find the effect of sickle cell anemia on height, weight and 
of children at King Abdulaziz Hospital in Al-Ahsa region. 
Methods 
This study was carried out retrospectively, and it was 
approved from institutional research committee and 
ethical review board. Clinically diagnosed SCD patients 
in children age groups (1-15 years) were included in the 
study. Adult SCD patients as well as patients with 
hemoglobinopathies other than SCD were excluded. 
Patient data was retrieved from the medical records at 
Division of Hematology/Oncology, Department of 
Pediatrics, King Abdulaziz Hospital, Al-Ahsa, Eastern 
region, Saudi Arabia. The data was analyzed using 
SPSS version 27. The growth parameters were 
compared between these different patient groups. The 
paired t-test was used to compare groups. P-values of 
0.05 were considered to be significant. 
Results  
This study included 53 children diagnosed with sickle cell 
disease (SCD) in King Abdulaziz Hospital Al-Ahsa from 
2013-2018. The age group for the selected sample size 
is from 0-12 years. The numbers of males were 31 (53%) 
and females were 22 (37%). The male to female ratio 
was 1.4:1. Moreover, most of the children diagnosed with 
SCD belonged to age group 0-4 (58.6%) and lowest to 
age group 5-9 years (32.8%). (Table 1a). Glucose-6-
phosphate dehydrogenase deficiency (G6PD) was found 
in 5 (9.4%) patients while mean HbF was 21.45% ± 9.33 
(Table 1b).  Out of 53 patients, 18 (34%) did not present 
with sickle cell crisis (non-crisis sickle cell group). All 
patients without sickle cell crisis had either high HbF 
level or G6PD deficiency. Therefore, high HbF levels and 
G6PD deficiency may have ameliorating effects on sickle 
cell patients. 
Variable Frequency Percentage Mean SD 
Gender Male 31 53 % 1.5 0.4 
Female 22 37 % 
Age at 
diagnosis 
0-4 34 58.6% 3.3 2.4 
5-9 19 32.8% 
Current 
age 
0-6 21 36.2% 7.1 2.7 
7-12 32 55.2% 
Table 1a: Gender and age groups of all patients included in the 
study. 
Variable Value Frequency Percentage 
RDW at Diagnosis High 47 88.7% 
Normal 5 9.4% 
Low 0 0 
RDW after clinical 
intervention 
High 44 83% 
Normal 6 11.3% 
Low 1 1.9% 
LDH High 45 84.9% 
Normal 1 1.9% 
Low 0 0 
Total bilirubin High 49 92.5% 
Normal 2 3.8% 
Low 0 0 
G6PD Positive 8 15.1% 
Negative 45 84.9% 
Mean HbF  21.45% ± 9.33  
Table 1b. Laboratory parameters of Sickle Cell Patients (* 
RDW=Red cell distribution width, LDH= Lactate dehydrogenase, 
G6PD=Glucose-6-phosphate dehydrogenase, HbF=Hemoglobin F) 
and farm wise.
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Patients included in this study had a variety of moderate 
to severe complications caused by the   disease. One 
patient (1.8%) was observed with leg ulcer. Bone X-ray 
images showed that 8.6% of patient bad bone 
abnormalities. Splenectomy is a therapeutic procedure 
that can be done in some severe sickle cell cases. 
Overall, 8.6% of patients with sickle cell disease had their 
spleen surgically removed (Figure 1 & Figure 2). 
 
Figure 1: Frequency of SCD patients with bone abnormalities 
and leg ulcer. 
 
Figure 2: Frequency of SCD patients with splenectomy. 
Overall, most of the male and female SCD patients had 
normal height and weight when compared with the 
international height and weight standards for healthy 
children (Table 2 and Table 3). 
Furthermore, the patients were divided into two groups, 
the patients suffering from recurrent sickle cell crisis (RC-
SC) group (35/53=66%) and patients with non-crisis 
sickle (NC-SC) cell group (18/53=34%). Chi-square test 
results showed that there was significant difference in 
weight of the patients in two groups at diagnosis and 
after clinical intervention (p-values: 0.04 and 0.03, 
respectively) (Table 4). Moreover, there was no 
statistically significant difference in height of both patient 
groups and body-mass index (BMI) at diagnosis (Table 
4). Nevertheless, significant difference in BMI of both 
groups was noted after clinical intervention (p=0.05).  
Crisis and non-crisis sickle cell patients 
Not all patients agree to hydroxyurea treatment. 
Treatment with hydroxyurea had on impact on sickle cell 
crisis management. Among group I patients (RC-SC) 
patients, 71.1% were taking hydroxyurea while 37.5% 
group 2 patients (NC-SC) provided consent for 
hydroxyurea urea. (P-value: 0.06). It necessitates needs 
to counsel all SCD patients and their families to take 
hydroxyurea.  
It was also found that hydroxyurea significantly 
affected corrected reticulocytes and WBC count in SCD 
patients. Corrected reticulocytes count in both at 
diagnosis and current was higher in non-hydroxyurea 
group (50%) as compared to hydroxyurea group (7.1%). 
WBCs count was low in 27.9% of patients taking 
hydroxyurea as compared to 12.5% of non-hydroxyurea 
group patients. The hematological parameters like 
corrected reticulocyte count (diagnosis and current) and 
WBC were statistically significant between hydroxyurea 
and non-hydroxyurea groups (p-value: 0.03, 0.005 and 
0.05) (Table 5) (Figures 3-5). It shows that hydroxyurea 
lowers reticulocytes and WBC count in sickle cell 
patients that can help in reducing severity of disease. 
Exact mechanisms involved in these beneficial effects of 
hydroxyurea for sickle cell patients through lowering 
down reticulocyte and WBC counts are needed to be 
investigated.  
 
Figure 3: Corrected reticulocytes count at diagnosis in 
hydroxyurea and non-hydroxyurea groups. 
 
Figure 4: Effect of hydroxyurea on current reticulocytes count. 
 
Figure 5: Comparison of white blood cell count between 
hydroxyurea and non-hydroxyurea groups.
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Among all growth parameters the current weight, 
height and BMI were lower in SCD patients not taking 
hydroxyurea as compared to hydroxyurea group. 
However, the p-value is more than 0.05 which is 
statistically not significant (Table 6). Studies with higher 
number of patients may explain the exact correlation of 
these growth parameters with hydroxyurea treatment.  
Overall, one third of SCD patients in Al-Ahsa region 
have mild disease and hydroxyurea can minimize the 
SCD severity through lowering corrected reticulocyte 
and WBC counts. Exact mechanisms of mild SCD and 
hydroxyurea in minimizing disease severity are needed 
to be elucidated.  
Discussion  
The aim of the study was to investigate the impact of 
sickle cell disease on children from Al-Ahsa region, 
Eastern Province, Saudi Arabia.  Our study shows that 
34% patients had no sickle cell crisis or other severe 
clinical manifestations. This is in accordance with 
previous studies reporting milder SCD in Eastern 
Province of Saudi Arabia and other regions [8, 12]. All of 
the SCD patients with milder disease had either high HbF 
(fetal hemoglobin) level or G6PD deficiency. Several 
other studies have reported protective effects of high 
HbF levels and G6PD deficiency in SCD [13, 14]. Level 
of HgF is controlled by multiple genetic loci likeHBB 
cluster, BCL11A, and HMIP-2 (HBS1L-MYB) and 
expression of these genes is under tight genetic control 
as manifested by involvement of many gene repressors,  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
enhancers and other factors. Silencing of repressors of 
HgF-inducing genes, for example, BCL11A repressor, is 
being investigated as innovative therapeutic strategy to 
develop novel medications for inducing high protective 
levels of HgF in SCD with initial promising results [15]. 
Several HgF-inducing drugs like hydroxyurea are 
already in clinical use [13, 15].  
There are ethnic and phenotypic variations in impact of 
SCD on growth parameters of patients in different parts 
of the world [9-11]. In our studies, overall male and 
female SCD patients had normal height and weight in 
comparison to international height and weight standards 
for healthy children. This is in accordance with a study 
published from USA, that reported no significant 
changes in height or weight of SCD on children and 
adolescents aged 6 to 18 years as compared to healthy 
population [9]. Nevertheless, weight was significantly 
lower in sickle cell crisis group as compared to non-crisis 
SCD group at diagnosis  (p=0.03) as well as after clinical 
interventions (0.04) in our studies. It could be 
Furthermore, non-crisis SCD group had more 
improvement in weight, height and BMI as compared to 
sickle-cell crisis group but it was not significant. It is 
understood as vaso-occlusive crisis is the major reason 
of major complications in SCD [16]. 
Hydroxyurea is the drug of choice for SCD patients, 
specifically for patients with vaso-occlusive crisis, but not 
all patients provided consent to take this medication. It is 
utilized as inducer of HgF expression that has protective 
effects for SCD patients [13, 14]. Our studies showed 
that SCD patients receiving hydroxyurea treatment had 
Age Male height Male weight Female height Female weight 
0-4 49.8-102.3 cm 3.3-16.3 kg 49.2-100 cm 3.3-15.4 kg 
5-9 109.2-133.3 cm 18.4-28.6 kg 107.9- 133.3 cm 17.9-28.1 kg 
0-6 49.8-115.5 cm 3.3-20.6 kg 49.2-115.5 cm 3.3-19.9 kg 
7-12 121.9-149.1 cm 22.9-39.9 kg 121.1-149.8 cm 22.4-41.5 kg 
Table 2: International normal ranges of height and weight in males and female children.  
Variables  Female  Male  P-value 
Normal  Low Normal Low  
Height at diagnosis  68.2% 31.8% 60% 40% 0.54 
Weight at diagnosis  59.1% 40.9% 56.7% 43.3% 0.86 
Current height 61.9% 38.1% 70% 29% 0.49 
Current weight  47.6% 52.4% 58.1% 41.9% 0.45 
Table 3: Height, weight and BMI before and after diagnosis compared between the groups. 
Variable Non-crisis Sickle cell crisis (18) 
Group 2 
SC crisis group(35) 
Group 1 
P-value 
Growth parameters Low Normal Low Normal   
Weight at diagnosis  71.4% 28.6% 29.4% 70.6% 0.04  
Current weight  64.7% 35.5% 33.3% 66.7% 0.03 
Height at diagnosis  68.6% 31.4% 52.9% 47.1% 0.27 
Current height 70.6% 29.4% 61.1% 38.9% 0.48 
BMI at diagnosis  5.7% 94.3% 82.4% 17.6% 0.17 
Current BMI 11.8% 88.2%  100% 0% 0.05 
Table 4: Comparison of Height, weight and BMI before and after diagnosis with sickle cell crisis and non-crisis sickle cell patients. 
Variable  Hydroxyurea   No hydroxyurea   P-value 
HIGH Low Normal High Low  
Corr. Retics at diagnosis  9.5% 2.4% 88.1% 37.5% 12.5% 50% 0.03 
Current corr. Retics 7.1% 7.1% 85.8% 50% 0% 50% 0.005 
Current WBCs 0% 27.9% 72.1% 12.5% 12.5% 75% 0.05 
Table 5: Comparison of hematological variables between hydroxyurea and non-hydroxyurea patients. 
Variable  Hydroxyurea   No hydroxyurea  P-value 
 Normal Low Normal Low  
Current height  66.7% 33.3% 71.4% 28.6% 0.8 
Current weight  53.3% 46.7% 57.1% 42.9% 0.85 
Current BMI  8.9% 91.1% 0% 100% 0.41 
Table 6: Comparison of growth parameters between hydroxyurea and non-hydroxyurea groups. 
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more improvement in body-mass index as compared to 
patients not receiving hydroxyurea. Similar results have 
been reported from investigators [17].  Our studies 
further showed decreased in WBC and corrected 
reticulocytes count in SCD patients receiving 
hydroxyurea, which is in accordance with other reports 
[17,18]. Although there is correlation between SCD, 
hydroxyurea treatment, lowering of WBC/reticulocytes 
and clinical improvement of SCD complications, exact 
mechanism of action of hydroxyurea still remains to be 
elusive [17-19].  Further studies by employing state-of-
the-art multi-omics technologies are required to find out 
factors associated with milder SCD in Al-Ahsa region of 
Saudi Arabia and to unravel cellular molecular 
mechanism of action in of hydroxyurea in SCD patients.  
Our study shows 18 (34%) did not present with sickle 
cell crisis possibly due to ameliorating effects high HbF 
levels and G6PD deficiency. Although growth 
parameters of SCD patients were not statistically 
different from international standards, there was 
significant difference between weight of SCD patients in 
recurrent sickle cell crisis group and non-crisis sickle 
(NC-SC) cell group at diagnosis and after clinical 
intervention (p-values: 0.04 and 0.03, respectively) that 
included hydroxyurea in eligible patients. The corrected 
reticulocyte (at diagnosis and after clinical intervention) 
and WBC counts were statistically significant between 
hydroxyurea and non-hydroxyurea groups (p-value < 
0.05). Overall, one third of SCD patients in Al-Ahsa 
region have mild disease and hydroxyurea can minimize 
the SCD severity through lowering corrected reticulocyte 
and WBC counts. Exact mechanisms of mild SCD and 
hydroxyurea in minimizing disease severity are needed 
to be elucidated. 
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